Sangamo Therapeutics Reports Strong Q3 2024 Growth

Sangamo Therapeutics Reports Strong Q3 2024 Growth - Nasdaq

In its third-quarter 2024 earnings report, Sangamo announced significant achievements, including a regulatory pathway for accelerated approval ...

Sangamo Therapeutics Reports Recent Business Highlights and ...

2024 ; Revenues. $. 49,412 ; Operating expenses: Research and development ; Research and development. 27,732.

Q3 2024 Sangamo Therapeutics Inc Earnings Call - Yahoo Finance

Nathalie Dubois- Stringfellow; Senior Vice President, Chief Development Officer; Sangamo Therapeutics Inc ... reports that Sangamo makes from time ...

Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue ...

Sangamo (SGMO) delivered earnings and revenue surprises of 233.33% and 86.11%, respectively, for the quarter ended September 2024.

Sangamo Therapeutics Reports Recent Business Highlights and ...

RICHMOND, Calif., November 12, 2024--Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results.

Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue ...

Sangamo Therapeutics ( SGMO Quick Quote SGMO - Free Report) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus ...

Sangamo price target raised to $9 from $3 at Barclays | Markets Insider

Sangamo Therapeutics Reports Strong Q3 2024 Growth · Sangamo files $500M mixed securities shelf · Sangamo reports Q3 EPS 4c, consensus (3c) ...

Sangamo Therapeutics Announces Third Quarter 2024 Conference ...

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company ...

Sangamo price target raised to $3 from $1 at Wells Fargo - TipRanks

Sangamo Therapeutics Reports Strong Q3 2024 Growth · Sangamo files $500M mixed securities shelf · Sangamo reports Q3 EPS 4c, consensus (3c).

Sangamo Biosciences: Promising Financial Position and Strategic ...

Related Stocks · Sangamo price target raised to $9 from $3 at Barclays · Sangamo Therapeutics Reports Strong Q3 2024 Growth · Sangamo files $500M ...

News Releases | Investor Relations - Sangamo Therapeutics, Inc.

(Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2024 financial results after the ...

Sangamo Therapeutics Inc. Stock Quote (U.S. - SGMO - MarketWatch

Q3 2024 Sangamo Therapeutics Inc Earnings Call Transcript. Nov. 13, 2024 at 12:06 a.m. ET on GuruFocus.com. Sangamo Therapeutics Reports Strong Q3 2024 Growth.

Sangamo Therapeutics Announces Third Quarter 2024 Conference ...

Sangamo Therapeutics (Nasdaq: SGMO) has announced it will release its third quarter 2024 financial results after market close on Tuesday, ...

Sangamo Therapeutics (SGMO) News Today - MarketBeat

HC Wainwright reissued a "buy" rating and issued a $5.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday. October 22, 2024 | ...

Sangamo Therapeutics Reports Recent Business Highlights and ...

“We are pleased with the progress being made in business development discussions across our portfolio, including our Fabry disease program. We ...

Sangamo Therapeutics (SGMO) Stock Price, News & Analysis

Sangamo Therapeutics Reports Strong Q3 2024 Growth. November 13 at 2:29 PM | markets.businessinsider.com. Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings ...

Sangamo Therapeutics, Inc. | Pioneering Genetic Cures

The Latest at Sangamo · Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results · Sangamo Therapeutics Announces ...

Sangamo Therapeutics Reports on Pfizer's Announcement of ...

Sangamo is eligible to earn from Pfizer up to $220 million in milestone payments upon the achievement of certain regulatory and commercial ...

Q3 2024 Sangamo Therapeutics Inc Earnings Call Transcript

Nov 12, 2024 / 09:30PM GMTOperator Good afternoon and welcome to the Sangamo Therapeutics third-quarter 2024 teleconference call.

Voyager Reports Third Quarter 2024 Financial and Operating Results

$24.6 million for the third quarter of 2024, compared to · $4.6 million for the same period in 2023. The increase was primarily due to increased ...